CD142(+)/CD61(+), CD146(+) and CD45(+) microparticles predict cardiovascular events in high risk patients following a Mediterranean diet supplemented with nuts
Por:
Chiva-Blanch, G, Crespo, J, Suades, R, Arderiu, G, Padro, T, Vilahur, G, Cubedo, J, Corella, D, Salas-Salvado, J, Aros, F, Martinez-Gonzalez, MA, Ros, E, Fito, M, Estruch, R, Badimon, L
Publicada:
1 jul 2016
Resumen:
Circulating microparticles (cMPs) are small phospholipid-rich microvesicles shed by activated cells that play a pivotal role in cell signalling related to the pathogenesis of atherothrombosis. We aimed to investigate the prognostic value of cMPs released from different vascular cells for cardiovascular event (CVE) presentation in asymptomatic patients at high cardiovascular risk factors under nutritional and pharmacologic treatment. This is a nested case-control study of 50 patients from the five-year follow-up prospective PREDIMED trial enrolled in the nuts arm of the Mediterranean diet (MedDiet-nuts). We randomly selected 25 patients who had suffered a CVE during follow-up and pair-matched them for sex, age, and classical CV risk factors to 25 patients who remained asymptomatic (no-CVE). Total Annexin V-(AV)(+) cMPs and cMPs from cells of the vascular compartment were quantified by flow cytometry at baseline and after one year follow-up. MedDiet-nuts and pharmacological treatment neither modified levels nor source of MP shedding in CVE patients. However, no-CVE patients showed 40-86 % decreased total AV(+), PAC-1(+)/AV(+), CD61(+)/AV(+), CD142(+)/CD61(+)/AV(+), CD62P(+)/AV(+), CD146(+)/AV(+), CD63(+)/AV(+) and CD11a(+)/AV(+) cMPs at one year follow-up (p <= 0.046, all). CD142(+)/CD61(+)/AV(+), CD146(+)/AV(+) and CD45(+)/AV(+) cMPs were decreased in no-CVE patients compared to CVE patients. A ROC-curve clustered model for CD142(+)/CD61(+)/AV(+), CD45(+)/AV(+) and CD146(+)/AV(+) cMPs predicted a future CVE [p<0.0001, AUC=0.805 (0.672 to 0.938)]. In patients at high CV risk profile treated with a controlled MedDiet supplemented with nuts and receiving up-to-date CV drug treatment, reduced cMPs derived from activated platelets, leukocytes and endothelial cells are predictive of protection against CVE within the next four years.
Filiaciones:
Chiva-Blanch, G:
Cardiovas Res Ctr CSIC ICCC, Barcelona, Spain
Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain
Crespo, J:
Cardiovas Res Ctr CSIC ICCC, Barcelona, Spain
Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain
Suades, R:
Cardiovas Res Ctr CSIC ICCC, Barcelona, Spain
Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain
Arderiu, G:
Cardiovas Res Ctr CSIC ICCC, Barcelona, Spain
Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain
Padro, T:
Cardiovas Res Ctr CSIC ICCC, Barcelona, Spain
Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain
Vilahur, G:
Cardiovas Res Ctr CSIC ICCC, Barcelona, Spain
Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain
Cubedo, J:
Cardiovas Res Ctr CSIC ICCC, Barcelona, Spain
Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain
Corella, D:
Inst Salud Carlos III ISCIII, CIBER Fisiopatol Obesidad & Nutr CIBEROBN, Madrid, Spain
Univ Valencia, Dept Prevent Med & Publ Hlth, Valencia, Spain
Salas-Salvado, J:
Inst Salud Carlos III ISCIII, CIBER Fisiopatol Obesidad & Nutr CIBEROBN, Madrid, Spain
Univ Rovira & Virgili, Inst Invest Sanitaries Pere Virgili, Hosp Univ St Joan, Human Nutr Unit, Reus, Spain
Aros, F:
Inst Salud Carlos III ISCIII, CIBER Fisiopatol Obesidad & Nutr CIBEROBN, Madrid, Spain
Univ Hosp Araba, Dept Cardiol, Vitoria, Spain
Martinez-Gonzalez, MA:
Inst Salud Carlos III ISCIII, CIBER Fisiopatol Obesidad & Nutr CIBEROBN, Madrid, Spain
Univ Navarra, Dept Epidemiol & Publ Hlth, Pamplona, Spain
Ros, E:
Inst Salud Carlos III ISCIII, CIBER Fisiopatol Obesidad & Nutr CIBEROBN, Madrid, Spain
Univ Barcelona, Hosp Clin, Inst Invest Biomed August Pi Sunyer IDIBAPS, Lipid Clin,Endocrinol & Nutr Serv, Barcelona, Spain
Fito, M:
Inst Salud Carlos III ISCIII, CIBER Fisiopatol Obesidad & Nutr CIBEROBN, Madrid, Spain
Inst Hosp Mar Invest Med IMIM, Cardiovasc Risk & Nutr Res Grp, Regicor Study Grp, Barcelona, Spain
Estruch, R:
Inst Salud Carlos III ISCIII, CIBER Fisiopatol Obesidad & Nutr CIBEROBN, Madrid, Spain
Univ Barcelona, IDIBAPS, Hosp Clin, Dept Internal Med, Barcelona, Spain
Badimon, L:
Cardiovas Res Ctr CSIC ICCC, Barcelona, Spain
Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain
Green Accepted
|